[Form 4] Ionis Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

4

07/17/2025 - 04:54 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

#1145 Ranked by Market Cap

N/A Ranked by Dividends

IONS Latest News

Sep 2, 2025

Ionis to present at upcoming investor conferences

Sep 2, 2025

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

Aug 21, 2025

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Jul 30, 2025

Ionis reports second quarter 2025 financial results and highlights progress on key programs

Jul 25, 2025

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

IONS Latest SEC Filings

Sep 3, 2025

[144] Ionis Pharmaceuticals, Inc. SEC Filing

Sep 3, 2025

[144] Ionis Pharmaceuticals, Inc. SEC Filing

Sep 3, 2025

[144] Ionis Pharmaceuticals, Inc. SEC Filing

Sep 3, 2025

[144] Ionis Pharmaceuticals, Inc. SEC Filing

Sep 2, 2025

[144] Ionis Pharmaceuticals, Inc. SEC Filing

IONS Stock Data

Market Cap 6.80B

Float 158.09M

Insiders Ownership 0.72%

Institutions Ownership 108.62%

Short Percent 7.27%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City CARLSBAD